Table 4 Univariate analysis of prognostic factors for progression-free survival (PFS) and overall survival (OS) in HGG patients
PFS | OS | ||||
|---|---|---|---|---|---|
n (%) | HR (95% CI) | P value | HR (95% CI) | P value | |
SSTR2 IHC | |||||
Negative | 19 (67.9) | 1 | 1 | ||
Positive | 9 (32.1) | 0.161 (0.037 to 0.704) | 0.015 | 0.083 (0.010 to 0.655) | 0.018 |
Age | |||||
> 60 | 11 (39.3) | 1 | 1 | ||
< 60 | 17 (60.7) | 0.484 (0.190 to 1.233) | 0.128 | 0.183 (0.053 to 0.631) | 0.007 |
Oligodendroglioma component | |||||
No | 21 (75.0) | 1 | 1 | ||
Yes | 7 (25.0) | 0.592 (0.210 to 1.672) | 0.322 | 0.361 (0.094 to 1.380) | 0.137 |
IDH1 | |||||
Wild type | 19 (67.9) | 1 | 1 | ||
Mutated | 9 (32.1) | 0.312 (0.102 to 0.950) | 0.040 | 0.167 (0.036 to 0.770) | 0.022 |
MGMT promoter | |||||
Unmethylated | 5 (18.5) | 1 | 1 | ||
Methylated | 22 (81.5) | 0.234 (0.073 to 0.753) | 0.015 | 0.229 (0.061 to 0.859) | 0.029 |
1p/19q co-deletion | |||||
No | 24 (85.7) | 1 | 1 | ||
Yes | 4 (14.3) | 0.780 (0.244 to 2.496) | 0.675 | 0.390 (0.081 to 1.871) | 0.239 |
EGFR amplification | |||||
No | 20 (71.4) | 1 | 1 | ||
Yes | 8 (28.6) | 2.083 (0.819 to 5.297) | 0.124 | 3.131 (0.986 to 9.943) | 0.053 |